VanEck Video Gaming and eSports ETF vs Novartis AG — how do they compare? VanEck Video Gaming and eSports ETF trades at $91.98, while Novartis AG trades at $151.57 (market cap $287.66B). The key difference: Novartis AG pays a 3.14% dividend while VanEck Video Gaming and eSports ETF pays none, and Novartis AG is trading nearer its 52-week high, VanEck Video Gaming and eSports ETF nearer its low. Which is the better fit depends on your goals.
| ESPO | NVS | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $122.30 | $168.62 |
52-Week Low | $85.25 | $113.50 |
Market Cap | — | $287.66B |
Enterprise Value | — | $327.68B |
Dividend Yield | — | 3.14% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novartis (NVS) trades at $150.36, down 1.96% with bearish technical signals. The company maintains strong profitability with 75.38% gross margins and 23.92% net income margin, though recent earnings show mixed results with one beat and two misses. Recent acquisitions including Myricx Bio for up to $1.5 billion expand the oncology pipeline, while regulatory approvals for Itvisma and positive drug trial data support growth prospects.
While analyst consensus leans cautious with 68% hold ratings, Novartis' robust cash flow generation and strategic pipeline investments provide long-term value. Key risks include execution challenges from recent acquisitions and competitive pressures in pharmaceuticals. The stock offers stability through strong fundamentals but faces near-term technical headwinds.
Trailing returns across standard periods
ESPO is a thematic ETF that invests in the global video gaming and eSports industry. It provides exposure to companies involved in game development, hardware, and streaming, including major firms like Tencent, Nintendo, and Electronic Arts.
Read more on ESPO →Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →